An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants.

Published

Journal Article

We developed an AIDS vaccine based on attenuated VSV vectors expressing env and gag genes and tested it in rhesus monkeys. Boosting was accomplished using vectors with glycoproteins from different VSV serotypes. Animals were challenged with a pathogenic AIDS virus (SHIV89.6P). Control monkeys showed a severe loss of CD4+ T cells and high viral loads, and 7/8 progressed to AIDS with an average time of 148 days. All seven vaccinees were initially infected with SHIV89.6P but have remained healthy for up to 14 months after challenge with low or undetectable viral loads. Protection from AIDS was highly significant (p = 0.001). VSV vectors are promising candidates for human AIDS vaccine trials because they propagate to high titers and can be delivered without injection.

Full Text

Duke Authors

Cited Authors

  • Rose, NF; Marx, PA; Luckay, A; Nixon, DF; Moretto, WJ; Donahoe, SM; Montefiori, D; Roberts, A; Buonocore, L; Rose, JK

Published Date

  • September 2001

Published In

Volume / Issue

  • 106 / 5

Start / End Page

  • 539 - 549

PubMed ID

  • 11551502

Pubmed Central ID

  • 11551502

Electronic International Standard Serial Number (EISSN)

  • 1097-4172

International Standard Serial Number (ISSN)

  • 0092-8674

Digital Object Identifier (DOI)

  • 10.1016/s0092-8674(01)00482-2

Language

  • eng